INFECTIOUS DISEASE CELLULAR IMMUNOTHERAPY

1 . A method for treating an infectious disease in a person comprising:

vaccinating a person having an infectious disease with a vaccine designed to induce an immune response against an infectious agent causing the infectious disease;

removing primed T-lymphocytes from the person;

stimulating the primed T-lymphocytes to differentiate into effector T-lymphocytes in vitro;

stimulating the effector T-lymphocytes to proliferate in vitro; and

infusing the effector T-lymphocytes back into the person.

2 . The method of claim 1 , further comprising:

upon infusing the effector T-lymphocytes to the person, infusing the person with interleukin-2.

3 . The method of claim 1 , wherein the vaccine includes an immunologic adjuvant.

4 . The method of claim 3 , wherein the immunologic adjuvant is a granulocyte macrophage colony stimulating factor.

5 . The method of claim 1 , wherein the primed T-lymphocytes are removed from the person using apheresis.

6 . The method of claim 1 , wherein the T-lymphocytes are stimulated to differentiate using anti-CD3.

7 . The method of claim 1 , wherein the infectious disease is HIV.

8 . The method of claim 1 , wherein the person is vaccinated at a plurality of injection sites.

9 . The method of claim 1 , wherein the person is vaccinated a plurality of times.

10 . The method of claim 1 , wherein the person is vaccinated at the time of initial diagnosis.

11 . The method of claim 1 , wherein the person is vaccinated with subpopulations of activated T-lymphocytes.

12 . A method for treating an infectious disease in a person comprising:

administering a first vaccine to a person having an infectious disease, wherein the first vaccine is designed to induce an immune response against an infectious agent causing the infectious disease;

upon administering the first vaccine, identifying an immune response exhibited by the person;

based on a determination that the immune response is below a predetermined immune response threshold, administering a second vaccine to the person;

removing primed T-lymphocytes from the person, wherein the primed T-lymphocytes are removed using apheresis;

treating the primed T-lymphocytes, in vitro, with a T-lymphocyte stimulus that stimulates the primed T-lymphocytes to differentiate into effector T-lymphocytes;

treating the effector T-lymphocytes, in vitro, with a cytokine that stimulates proliferation of effector T-lymphocytes; and

infusing the effector T-lymphocytes back into the person.

13 . The method of claim 12 , further comprising:

combining the first vaccine with an immunologic agent to yield the second vaccine.

14 . The method of claim 13 , wherein the immunologic adjuvant is a granulocyte macrophage colony stimulating factor.

15 . The method of claim 12 , wherein the first vaccine and the second vaccine are the same.

16 . The method of claim 12 , wherein the cytokine that stimulates proliferation of the effector T-lymphocytes is interleukin-2.

17 . The method of claim 12 , wherein the T-lymphocyte stimulus that stimulates the primed T-lymphocytes to differentiate into effector T-lymphocytes is anti-CD3.

18 . The method of claim 17 , wherein a concentration of anti-CD3 is between 0.01 and 100 nanograms/milliliter.

19 . The method of claim 12 , wherein the primed T-lymphocytes are removed from the person using apheresis.

20 . The method of claim 12 , further comprising:

upon infusing the person with the effector T-lymphocytes, infusing the person with interleukin-2.